FDA Pooled Analysis: Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant.
9 Nov, 2021 | 01:05h | UTCOverall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
A pooled analysis of phase III trials of fulvestrant plus either CDK4/6 inh or placebo in pts with HR+/HER2- advanced-stage #breastcancer shows an mOS benefit of 7.1 months (over a mFU of 43.7 months) favouring CDK4/6i (HR 0.77, 95% CI 0.68–0.88): https://t.co/ZMa0J8gS8Q #bcsm
— NatureRevClinOncol (@NatRevClinOncol) October 21, 2021